Skip to main content

Kondylome bei HIV-Infizierten

Genital warts in HIV-infected individuals

Der Hautarzt volume 68, pages 192–198 (2017)Cite this article

Zusammenfassung

Kondylome sind bei HIV-infizierten Patienten wesentlich häufiger als bei HIV-negativen Personen. Kondylome HIV-Positiver unterscheiden sich von denen HIV-Negativer in der Ausdehnung, im Auftreten an ungewöhnlicheren Lokalisationen, im HPV (humane Papillomviren)-Typenspektrum, in der Rezidivneigung sowie im Entartungsrisiko. Etwa 18–56 % der Kondylome HIV-positiver Patienten enthalten hochgradige Dysplasien. Aus diesem Grund sollten Kondylome bei HIV-Infizierten vorzugsweise ablativ entfernt und histopathologisch evaluiert werden. Durch die geschlechtsneutrale prophylaktische HPV-Impfung von HPV-naiven Jungen und Mädchen könnte zukünftig eine deutliche Reduktion von Kondylomen auch in dieser Patientengruppe erreicht werden.

Abstract

Anogenital warts (condylomata acuminata) are much more frequent in human immunodeficiency (HIV)-positive patients compared to HIV-negative individuals. Anogenital warts of HIV-infected patients differ from those of HIV-negative individuals with respect to their spread, occurrence on more unusual anatomical sites, human papillomavirus (HPV)-type spectrum, tendency to recur, and risk of malignant transformation. Between 18 and 56% of anogenital warts of HIV-positive patients harbor high-grade dysplasia. Therefore, anogenital warts of HIV-infected patients should be preferentially treated with ablative methods and should be evaluated histopathologically. Gender-neutral prophylactic HPV vaccination of HPV-naive boys and girls could also lead to a significant reduction of anogenital warts in this patient group in the future.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Abramowitz L, Benabderrahmane D, Ravaud P et al (2007) Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: Prevalence and associated factors. AIDS 21:1457–1465

    Article  PubMed  Google Scholar 

  2. Ali H, Donovan B, Wand H et al (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: National surveillance data. BMJ 346:f2032

    Article  PubMed  Google Scholar 

  3. Bhageerathy PS, Cecilia M, Sebastian A et al (2014) Human papilloma virus-16 causing giant condyloma acuminata. J Surg Case Rep. doi:10.1093/jscr/rjt126

    Article  PubMed  Google Scholar 

  4. Braun SA, Jansen TM, Homey B et al (2015) Successful therapy of condylomata acuminata with ingenol mebutate. Hautarzt 66:223–225

    CAS  Article  PubMed  Google Scholar 

  5. Chirgwin KD, Feldman J, Augenbraun M et al (1995) Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women. J Infect Dis 172:235–238

    CAS  Article  PubMed  Google Scholar 

  6. Coskuner ER, Ozkan TA, Karakose A et al (2014) Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: A randomized study. J Sex Med 11:2785–2791

    Article  PubMed  Google Scholar 

  7. De Camargo CC, Tasca KI, Mendes MB et al (2014) Prevalence of anogenital warts in men with HIV/AIDS and associated factors. Open AIDS J 8:25–30

    Article  PubMed  PubMed Central  Google Scholar 

  8. Dinleyici M, Saracoglu N, Eren M et al (2015) Giant Condyloma Acuminate due to human Papillomavirus type 16 in an infant successfully treated with topical Imiquimod therapy. Dermatol Reports 7:6134

    Article  PubMed  PubMed Central  Google Scholar 

  9. Dolev JC, Maurer T, Springer G et al (2008) Incidence and risk factors for verrucae in women. AIDS 22:1213–1219

    Article  PubMed  PubMed Central  Google Scholar 

  10. Drolet M, Benard E, Boily MC et al (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis 15:565–580

    Article  PubMed  PubMed Central  Google Scholar 

  11. Dupin N (2004) Genital warts. Clin Dermatol 22:481–486

    Article  PubMed  Google Scholar 

  12. Esser S, Kreuter A, Oette M et al (2015) German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: Prevention, diagnosis, and treatment. J Dtsch Dermatol Ges 13:1302–1319

    Article  PubMed  Google Scholar 

  13. Fuchs W, Wieland U, Skaletz-Rorowski A et al (2016) The male ScreenING Study: Prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany. J Eur Acad Dermatol Venereol 30:995–1001

    CAS  Article  PubMed  Google Scholar 

  14. Giuliano AR, Palefsky JM, Goldstone S et al (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364:401–411

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. Gormley RH, Kovarik CL (2012) Human papillomavirus-related genital disease in the immunocompromised host: Part I. J Am Acad Dermatol 66(867):e861–e814

    Google Scholar 

  16. Gormley RH, Kovarik CL (2012) Human papillomavirus-related genital disease in the immunocompromised host: Part II. J Am Acad Dermatol 66(883):e881–e817

    Google Scholar 

  17. Grussendorf-Conen EI (1997) Anogenital premalignant and malignant tumors (including Buschke-Lowenstein tumors). Clin Dermatol 15:377–388

    CAS  Article  PubMed  Google Scholar 

  18. Hernandez-Suarez G, Pineros M, Vargas JC et al (2013) Human papillomavirus genotypes in genital warts in Latin America: a cross-sectional study in Bogota, Colombia. Int J STD AIDS 24:567–572

    CAS  Article  PubMed  Google Scholar 

  19. Hildesheim A, Gonzalez P, Kreimer AR et al (2016) Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol 215:212

    Article  PubMed  Google Scholar 

  20. Jiamton S, Leeyaphan C, Maneeprasopchoke P et al (2014) Prevalence and clinical manifestations of male patients with Anogenital warts attending a sexually transmitted disease clinic prior Hpv vaccine recommendation. Southeast Asian J Trop Med Public Health 45:1337–1343

    PubMed  Google Scholar 

  21. Komlos KF, Kocjan BJ, Kosorok P et al (2012) Tumor-specific and gender-specific pre-vaccination distribution of human papillomavirus types 6 and 11 in anogenital warts and laryngeal papillomas: A study on 574 tissue specimens. J Med Virol 84:1233–1241

    Article  PubMed  Google Scholar 

  22. Kraut AA, Schink T, Schulze-Rath R et al (2010) Incidence of anogenital warts in Germany: A population-based cohort study. BMC Infect Dis 10:360

    Article  PubMed  PubMed Central  Google Scholar 

  23. Kreuter A, Siorokos C, Oellig F et al (2016) High-grade Dysplasia in anogenital warts of HIV-positive men. JAMA Dermatol 152:1225–1230

    Article  PubMed  Google Scholar 

  24. Kreuter A, Wieland U (2013) Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. J Am Acad Dermatol 68:179–180

    Article  PubMed  Google Scholar 

  25. Maniar KP, Ronnett BM, Vang R et al (2013) Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: Independent lesions due to different HPV types occurring in immunocompromised patients. Am J Surg Pathol 37:53–60

    Article  PubMed  PubMed Central  Google Scholar 

  26. Mccloskey JC, Metcalf C, French MA et al (2007) The frequency of high-grade intraepithelial neoplasia in anal/perianal warts is higher than previously recognized. Int J STD AIDS 18:538–542

    CAS  Article  PubMed  Google Scholar 

  27. Patel H, Wagner M, Singhal P et al (2013) Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 13:39

    Article  PubMed  PubMed Central  Google Scholar 

  28. Pimenoff VN, Felez-Sanchez M, Tous S et al (2015) Disagreement in high-grade/low-grade intraepithelial neoplasia and high-risk/low-risk HPV infection: Clinical implications for anal cancer precursor lesions in HIV-positive and HIV-negative MSM. Clin Microbiol Infect 21(605):e611–e609

    Google Scholar 

  29. Richel O, Hallensleben ND, Kreuter A et al (2013) High-resolution anoscopy: Clinical features of anal intraepithelial neoplasia in HIV-positive men. Dis Colon Rectum 56:1237–1242

    Article  PubMed  Google Scholar 

  30. Robert-Koch-Institut (2016) Anwendung des neunvalenten Impfstoffs gegen Humane Papillomviren (HPV). Epidemiol Bull 16:137

    Google Scholar 

  31. Robert Koch-Institut (2016) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiol Bull 34:312

    Google Scholar 

  32. Schiller JT, Lowy DR (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 10:681–692

    CAS  Article  PubMed  Google Scholar 

  33. Schiller JT, Müller M (2015) Next generation prophylactic human papillomavirus vaccines. Lancet Oncol 16:e217–e225

    CAS  Article  PubMed  Google Scholar 

  34. Schopf RE (2016) Ingenol mebutate gel is effective against anogenital warts – a case series in 17 patients. J Eur Acad Dermatol Venereol 30:1041–1043

    CAS  Article  PubMed  Google Scholar 

  35. Siegenbeek Van Heukelom ML, Richel O, De Vries HJ et al (2016) Low- and high-risk human papillomavirus genotype infections in intra-anal warts in HIV-positive men who have sex with men. Br J Dermatol 175:735–743

    CAS  Article  PubMed  Google Scholar 

  36. Snoeck R, Bossens M, Parent D et al (2001) Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 33:597–602

    CAS  Article  PubMed  Google Scholar 

  37. Stanley M (2012) Perspective: Vaccinate boys too. Nature 488:S10

    CAS  Article  PubMed  Google Scholar 

  38. Stier EA, Goldstone SE, Einstein MH et al (2013) Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS 27:545–551

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. Sturegard E, Johansson H, Ekstrom J et al (2013) Human papillomavirus typing in reporting of condyloma. Sex Transm Dis 40:123–129

    PubMed  Google Scholar 

  40. Swedish KA, Factor SH, Goldstone SE (2012) Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 54:891–898

    Article  PubMed  Google Scholar 

  41. Wieland U, Kreuter A (2011) HPV vaccine against HPV infection and disease in males. N Engl J Med 364:2163

    CAS  Article  PubMed  Google Scholar 

  42. Wikstrom A, Vassilaki I, Hedblad MA et al (2013) The spectrum of genital human papillomavirus infection among men attending a Swedish sexually-transmitted infections clinic: Human papillomavirus typing and clinical presentation of histopathologically benign lesions. Acta Derm Venereol 93:223–227

    Article  PubMed  Google Scholar 

  43. Wilkin TJCH, Cespedes M et al (2016) ACTG A5298: A phase 3 trail of quadrivalent HPV vaccine in older HIV+ adults. Conference on Retroviruses and Opportunistic Infections (CROI) Abstract 161. http://www.croiconference.org/scientific-program/electronic-materials/croi-2016. Zugegriffen: 05.01.2017

    Google Scholar 

  44. Workowski KA, Bolan GACDC (2015) Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64:1–137

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Institut für Virologie, Nationales Referenzzentrum für Papillom- und Polyomaviren, Universität zu Köln, 50935, Köln, Deutschland

    U. Wieland

  2. Klinik für Dermatologie, Venerologie und Allergologie, HELIOS St. Elisabeth Klinik Oberhausen, Universität Witten-Herdecke, 46045, Oberhausen, Deutschland

    A. Kreuter

Authors
  1. U. Wieland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Kreuter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Wieland.

Ethics declarations

Interessenkonflikt

U. Wieland gibt an, dass kein Interessenkonflikt besteht. A. Kreuter hat Referentenhonorare von Sanofi Pasteur MSD erhalten und war im Advisory Board von Sanofi Pasteur MSD tätig.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wieland, U., Kreuter, A. Kondylome bei HIV-Infizierten. Hautarzt 68, 192–198 (2017). https://doi.org/10.1007/s00105-017-3938-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-017-3938-z

Schlüsselwörter

  • Anogenitale Warzen
  • Genitalwarzen
  • Condylomata acuminata
  • Humanes Papillomvirus
  • Impfung

Keywords

  • Anogenital warts
  • Genital warts
  • Condylomata acuminata
  • Human papillomavirus
  • Vaccination